Cite
HARVARD Citation
Barba, C. et al. (2021). Intensive rituximab regimen in immune‐mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment. British journal of haematology. pp. e21-e25. [Online].